In neurodegenerative diseases, particularly Parkinson's disease, PJ34, a selective PARP1 inhibitor, has shown significant neuroprotective effects in experimental traumatic brain injury (TBI) by reducing neuronal death and microglial activation [26]. The gene discussed is PARP1; the disease is neurodegenerative disease.